PEDIATRICS Vol. 19 No. 4 April 1957, pp. 614-618
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Livingston, S.
Right arrow Articles by Pauli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livingston, S.
Right arrow Articles by Pauli, L.

CELONTIN® (PM-396) IN THE TREATMENT OF EPILEPSY

Samuel Livingston M.D.1 and Lydia Pauli M.D.1

1 Department of Pediatrics, Johns Hopkins University Medical School and the Epilepsy Clinic of The Johns Hopkins Hospital

One hundred thirty-six patients with epilepsy, mostly children, were treated with Celontin® for periods ranging from 6 to 15 months. The maximum dosage of one or more other anticonvulsant agents administered for periods of 1 year or more had previously proved inffective in controlling seizures in 85 of these patients.

Celontin® was effective in controlling minor motor and psychomotor seizures in this group of patients.

The frequency of spells was reduced in some of the patients with petit mal epilepsy. Patients with major motor seizures were not significantly benefited by this drug.

Side effects were experienced by 18 of the 136 patients treated. Drowsiness was the most frequently occurring side effect. There were no irreversible toxic disturbances.

Submitted on July 30, 1956
Accepted on August 21, 1956